UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 12, 2013

 

ARTHROCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-027422

 

94-3180312

(State or other jurisdiction

 

(Commission File Number)

 

(I.R.S. Employer Identification

of Incorporation)

 

 

 

No.)

 

7000 West William Cannon, Building One

Austin, TX 78735

(Address of principal executive offices, including zip code)

 

(512) 391-3900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

A special meeting of stockholders (the “Special Meeting”) of ArthroCare Corporation (the “Company”) was held on December 12, 2013.  At the Special Meeting, the Company’s stockholders voted on two proposals described in detail in the Company’s Proxy Statement, dated October 23, 2013, and cast their votes as follows:

 

1.              Proposal 1: To approve an amendment to the Company’s Certificate of Incorporation amending the Certificate of Designations of the Series A 3.00% Convertible Preferred Stock to permit the size of the Board of Directors of the Company to be increased to a maximum of nine persons:

 

Votes For

 

Votes
Against

 

Abstentions

 

30,266,227

 

17,914

 

11,179

 

 

2.              Proposal 2: For the election of Fabiana Lacerca-Allen as a member of the Board of Directors of the Company to serve until the Company’s next annual meeting or until her successor is duly qualified and elected:

 

Votes For

 

Votes
Against

 

Abstentions

 

30,256,376

 

24,104

 

14,839

 

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARTHROCARE CORPORATION

 

 

 

 

Date: December 12, 2013

 

 

 

 

 

By:

/s/ David Fitzgerald

 

David Fitzgerald

 

President and Chief Executive Officer

 

3